The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Diverse approaches for the enhancement of oral drug bioavailability
Abstract
In conscious and co‐operating patients, oral drug delivery remains the preferable route of drug administration. However, not all drugs possess the desirable physicochemical and pharmacokinetic properties which favor oral administration mainly due to poor bioavailability. This has in some cases led to the choice of other routes of administration, which may compromise the convenience and increase the risk of non‐compliance. Poor bioavailability has necessitated the administration of higher than normally required oral doses which often leads to economic wastages, risk of toxicity, erratic and unpredictable responses. The challenge over the years has been to design techniques that will allow oral administration of most drugs, irrespective of their properties, to achieve a therapeutic systemic availability. This will be a worthy achievement since over 90% of therapeutic compounds are known to possess oral bioavailability limitations. In this review, an attempt has been made to explore various approaches that have been used in recent years to improve oral drug bioavailability, including physical and chemical means. This review strives to provide a comprehensive overview of advances made over the past 10 years (2000–2010) in the improvement of the oral bioavailability of drugs. Briefly, the design of prodrugs to bypass metabolism or to enhance solubility as well as modification of formulation techniques such as the use of additives, permeation enhancers, solubilizers, emulsifiers and non‐aqueous vehicles have been discussed. Arising approaches, such as formulation modification techniques; novel drug delivery systems, which exploit the gastrointestinal regionality of drugs, and include the pharmaceutical application of nanotechnology as an emerging area in drug delivery; inhibition of efflux pumps; and inhibition of presystemic metabolism have been more extensively addressed. This critical review sought to assess each method aimed at enhancing the oral bioavailability of drugs in terms of the purpose, scientific basis, limitations, commercial application, as well as the areas in which current research efforts are being focused and should be focused in the future. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Is the oral route possible for peptide and protein drug delivery?
Morishita, M., & Peppas, N. A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.005 · Cited by 515 · cited 3×
“This is a more promising approach to pharmaceutical research in pharmacotherapy than the development of new drug entities as most new drug candidates face similar problems [13].”
BackgroundInfluentialClinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Clinical pharmacokinetics of statins
Garcia, M. J., Reinoso, R. F., Sanchez Navarro, A., & Prous, J. R. (2003) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2003.25.6.769652 · Cited by 121
Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts
Pang, K. S., Weiss, M., & Macheras, P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902030 · Cited by 61
Cited by
Oral delivery of anticancer drugs: Challenges and opportunities
Thanki, K., Gangwal, R. P., Sangamwar, A. T., & Jain, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.020 · Cited by 499
BCS class IV drugs: Highly notorious candidates for formulation development
Ghadi, R., & Dand, N. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.014 · Cited by 361
Biomimetic tissues on a chip for drug discovery
Ghaemmaghami, A. M., Hancock, M. J., Harrington, H., Kaji, H., & Khademhosseini, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.029 · Cited by 359
Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
McClements, D. J., Li, F., & Xiao, H. (2015) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-032814-014043 · Cited by 315
Metadata
- Authors
- Fasinu, P., Pillay, V., Ndesendo, V. M. K., du Toit, L. C., & Choonara, Y. E.
- Venue
- Biopharmaceutics & Drug Disposition
- Publisher
- Wiley
- Published
- 2011-04-07
- Volume
- 32
- Issue
- 4
- Pages
- 185-209
- ISSN
- 0142-2782 (ISSN-L)
- 1099-081X
- OpenAlex
- W2021386451
- Cited by
- 166
- References
- 5
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.